Abeille Pharmaceuticals Inc., of Princeton, N.J., appointed Zsolt Lavotha and James Warren to its board.

Acologix Inc., of Hayward, Calif., appointed Patrick Murphy vice president, CMD and operations.

ActivBiotics Inc., of Lexington, Mass., appointed Suzanne Cadden vice president, regulatory affairs and Canadian operations, and Jeff Courtney to its board.

Advanced Cell Technology Inc., of Worcester, Mass., appointed Shi-Jiang Lu senior scientist, and Sandy Becker, Gary DiPerma, Qiang Feng, Katherine Holton and Rebecca Ramos-Kelsey senior research associates.

Alfacell Corp., of Bloomfield, N.J., appointed Robert Love chief financial officer.

Amazon Biotech Inc., of New York, appointed Jeffrey Gilbert to its scientific advisory board.

Arginox Pharmaceuticals, of Menlo Park, Calif., appointed David Hathaway chief medical officer.

Auxilium Pharmaceuticals Inc., of Norristown, Pa., appointed James Fickenscher chief financial officer.

BioAlliance Pharma, of Paris, appointed Piers Morgan chief financial officer.

BioXell SpA, of Milan, Italy, appointed Alex Martin chief financial officer.

Borean Pharma A/S, of Aarhus, Denmark, appointed John Nieland vice president of preclinical research.

Cambrex Corp., of East Rutherford, N.J., appointed David Bethune to its board.

Cell Genesys Inc., of South San Francisco, appointed Sharon Tetlow senior vice president and chief financial officer.

Cellegy Pharmaceuticals Inc., of Brisbane, Calif., appointed Frank Malinoski vice president, research and development of its women's health operation.

Cephalon Inc., of Frazer, Pa., appointed Vaughn Kailian to its board.

Cubist Pharmaceuticals Inc., of Lexington, Mass., appointed David Mantus vice president, regulatory affairs.

CyGenics Ltd., of Melbourne, Australia, appointed Anne Altmann medical director, Katie Allen medical consultant, Sahar Bassal research and clinical trials coordinator, and Cynthia Elliot director of quality assurance and regulatory affairs.

Digene Corp., of Gaithersburg, Md., appointed Frank Ryan to its board.

Dyax Corp., of Cambridge, Mass., appointed Thomas Beck executive vice president, business and product development.

The National Cancer Coalition, of New Orleans, formed a scientific advisory board consisting of Robert Getzenberg, Jesse Jaynes, Mary Ann Richardson and Michael Wong.

The National Institute of Allergy and Infectious Diseases appointed Michael Kurilla associate director for biodefense product development, and director of the office of biodefense research activities within the division of microbiology and infectious diseases.

Peptimmune Inc., of Cambridge, Mass., appointed Jose-Carlos Gutierrez-Ramos vice president, research and development, and chief scientific officer. It also named Christine Blumhardt vice president, regulatory affairs and quality assurance.

RegeneRx Biopharmaceuticals Inc., of Bethesda, Md., appointed Gabriel Sosne to its medical and scientific advisory board.

Santhera Pharmaceuticals, of Liestal, Switzerland, appointed Barbara Heller chief financial officer.

Speedel Holding Ltd., of Basel, Switzerland, appointed Rolf Hanggi a nonexecutive member of its board.

TransMolecular Inc., of Birmingham, Ala., appointed Hans Mueller and Mark Ahn to its board.

TyRx Pharma Inc., of Monmouth Junction, N.J., appointed William McJames vice president of product development, and Mason Diamond vice president of clinical and regulatory affairs.

Vertex Pharmaceuticals Inc., of Cambridge, Mass., re-elected Roger Brimblecombe, Stuart Collinson and Matthew Emmens to its board, and it appointed Eugene Cordes a nonexecutive member of the board, and Joshua Boger company president, in addition to his roles as chairman and CEO.

Xanthus Life Sciences, of Cambridge, Mass., appointed Robert Capizzi senior vice president and chief medical officer.

No Comments